Sustainably produced food ingredients - BRAIN AG and Roquette successfully complete research collaboration
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous
Sustainably produced food ingredients
BRAIN AG and Roquette successfully complete research collaboration
Within this collaboration BRAIN has identified, developed and optimized biological resources for such sustainable production processes. The R&D work was partly based on BRAIN's huge BioArchive containing more than 53,000 comprehensively characterized, cultivable microorganisms as well as a variety of new enzymes and metabolic pathways.
Dr Guido Meurer, Executive Vice President Producer Strain Development at BRAIN AG, said: "The collaboration with Roquette is a success story, we are very proud of. We are looking forward to a successful expansion of further joined strategic programs."
For BRAIN AG the now completed research collaboration for sustainable food ingredient production processes is business relevant for the segment BioScience, which mainly comprises exclusive R&D-collaborations with industry partners. Both parties have agreed to not disclose any more details.
In recent months, the two companies have initiated new collaboration projects. In August 2016, BRAIN AG, Roquette and AnalytiCon Discovery GmbH started the DOLCE program for the development of next generation natural sweetening solutions. In November 2016 two major food categories joined the DOLCE program.
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. www.brain-biotech.de/en.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
|Company:||B.R.A.I.N. Biotechnology Research And Information Network AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|